Last-Resort drug made available for stubborn lung infections
NCT ID NCT04334070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides Lamprene (clofazimine), a drug normally used for leprosy, to adults with NTM infections that haven't responded to other treatments or caused intolerable side effects. Patients take 100 mg of clofazimine daily as part of a multi-drug regimen. The goal is to offer a potential option when no standard therapies are left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Clofazimine (Lamprene), a drug taken as 100 mg capsules daily with food, as part of a multi-drug regimen
What this could lead to
If this program helps, it could offer a treatment option for people with hard-to-treat NTM infections who have run out of other choices.
What could go wrong
This is an expanded access program, not a formal trial, so results are not systematically collected. Clofazimine is not FDA-approved for NTM, and its effectiveness and safety for this use are not fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-TUBERCULOUS MYCOBACTERIAL (NTM) INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••